AstraZeneca Pharma to launch Trastuzumab deruxtecan in January 2024

21 Dec 2023 Evaluate

AstraZeneca Pharma India is planning to launch Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder (Enhertu) in January 2024 in India. Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.


Astrazeneca Pharma I Share Price

8606.35 112.45 (1.32%)
28-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.45
Dr. Reddys Lab 1144.05
Cipla 1441.70
Lupin 2026.50
Zydus Lifesciences 885.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...